secwatch.observer — SEC 8-K summary
======================================

Issuer:     Solid Biosciences Inc. (SLDB)
CIK:        0001707502
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0001193125-23-004189
Event type: leadership
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Solid Biosciences appoints Kevin Tan CFO, discloses $214M cash, targets SGT-003 IND in H2 2023
--------------------------------------------------------------------------------

- Kevin Tan appointed CFO effective Jan 9, 2023; base salary $425k, 40% bonus target, equity grants.
- Preliminary cash and investments $214M as of Dec 31, 2022 (unaudited).
- Company anticipates submitting IND for SGT-003 in H2 2023 with patient dosing in late 2023.
- Tan previously served as CFO of Selecta Biosciences and Treasurer at Sarepta Therapeutics.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1707502/000119312523004189/0001193125-23-004189-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1707502/000119312523004189/d426001d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-004189

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer